Year Founded
2015
Ownership
Private
Employees
~100
Therapeutic Areas
EndocrinologyNeurologyMetabolic Disorders
Stage
Phase 1
Modalities
Small moleculeAntibody-based immunotherapy

Confo Therapeutics General Information

Lead candidate CFTX-1554 in Phase 1 for neuropathic pain; platform generating multiple preclinical candidates

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Ghent,
Belgium

Drug Pipeline

CFTX-1554
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Confo Therapeutics's pipeline data

Book a demo

Key Partnerships

Regeneron, Roche, Lundbeck, Daiichi Sankyo, AbCellera, Lilly

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Confo Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCJul 26, 2024$65.2MCompletedPhase 1
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Confo Therapeutics's complete valuation and funding history, request access »

Confo Therapeutics Investors

Ackermans & van Haaren
Investor Type: Venture Capital
Holding: Minority
BioGeneration Ventures
Investor Type: Venture Capital
Holding: Minority
Capricorn Health-tech Fund
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 13 investors. Get the full list »